MA41988A - Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa - Google Patents
Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampaInfo
- Publication number
- MA41988A MA41988A MA41988A MA41988A MA41988A MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A MA 41988 A MA41988 A MA 41988A
- Authority
- MA
- Morocco
- Prior art keywords
- azabenzimidazoles
- receiver modulators
- ampa
- ampa receiver
- compounds
- Prior art date
Links
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention porte sur des composés de formule (l) et sur leurs sels, n-oxydes et solvates, de qualité pharmaceutique. L'invention concerne également des compositions pharmaceutiques comprenant des composés de formule (i), et des méthodes d'utilisation de ces composés de formule (i).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562154313P | 2015-04-29 | 2015-04-29 | |
PCT/US2016/029801 WO2016176460A1 (fr) | 2015-04-29 | 2016-04-28 | Azabenzimidazoles et leur utilisation en tant que modulateurs des récepteurs ampa |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41988A true MA41988A (fr) | 2018-07-03 |
MA41988B1 MA41988B1 (fr) | 2021-03-31 |
Family
ID=56008859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA41988A MA41988B1 (fr) | 2015-04-29 | 2016-04-28 | Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa |
Country Status (39)
Country | Link |
---|---|
US (4) | US11312712B2 (fr) |
EP (3) | EP4144736A1 (fr) |
JP (2) | JP6800886B2 (fr) |
KR (2) | KR20170140382A (fr) |
CN (1) | CN107835814B (fr) |
AR (1) | AR104447A1 (fr) |
AU (2) | AU2016255434C1 (fr) |
BR (2) | BR112017023147B1 (fr) |
CA (1) | CA2983826A1 (fr) |
CO (1) | CO2017011017A2 (fr) |
CR (1) | CR20170484A (fr) |
CY (1) | CY1124059T1 (fr) |
DK (1) | DK3288940T5 (fr) |
EA (1) | EA033281B1 (fr) |
EC (1) | ECSP17074645A (fr) |
ES (1) | ES2865330T3 (fr) |
GT (1) | GT201700231A (fr) |
HK (1) | HK1252249A1 (fr) |
HR (1) | HRP20210403T1 (fr) |
HU (1) | HUE053943T2 (fr) |
IL (1) | IL254848B (fr) |
JO (1) | JO3654B1 (fr) |
LT (1) | LT3288940T (fr) |
MA (1) | MA41988B1 (fr) |
MD (1) | MD3288940T2 (fr) |
MX (1) | MX2017013886A (fr) |
MY (1) | MY194104A (fr) |
NI (1) | NI201700129A (fr) |
PH (1) | PH12017501816A1 (fr) |
PL (1) | PL3288940T3 (fr) |
PT (1) | PT3288940T (fr) |
RS (1) | RS61688B1 (fr) |
SG (1) | SG11201708190UA (fr) |
SI (1) | SI3288940T1 (fr) |
TW (1) | TWI706952B (fr) |
UA (1) | UA120304C2 (fr) |
UY (1) | UY36654A (fr) |
WO (1) | WO2016176460A1 (fr) |
ZA (1) | ZA201708065B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017023038A2 (pt) * | 2015-04-29 | 2018-07-03 | Janssen Pharmaceutica Nv | imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa |
CN107383004B (zh) * | 2017-07-05 | 2020-04-17 | 浙江大学 | 2-氨基咪唑并吡啶类衍生物及制备和应用 |
CN111315735B (zh) * | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
EP3693360B1 (fr) * | 2017-10-06 | 2023-12-13 | Takeda Pharmaceutical Company Limited | Composés hétérocycliques |
RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
EP3873905A4 (fr) * | 2018-10-30 | 2022-08-17 | Repare Therapeutics Inc. | Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr |
KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
US20240076285A1 (en) * | 2020-12-16 | 2024-03-07 | Shankar Venkatraman | Compounds and compositions for treating conditions associated with sting activity |
CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
CN115304599A (zh) * | 2022-09-20 | 2022-11-08 | 浙大宁波理工学院 | 一种3-溴-6-异丙基-1氢-哌咯[2,3-b]并吡啶及其制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
CN1051313A (zh) | 1990-11-07 | 1991-05-15 | 鞍山市振东工业尼龙厂 | 尼龙球磨罐及其热装工艺 |
GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
TW251284B (fr) | 1992-11-02 | 1995-07-11 | Pfizer | |
CA2183084A1 (fr) | 1994-02-10 | 1995-08-17 | John Eugene Macor | Derives du 5-heteroarylindole |
US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
UA54403C2 (uk) | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму |
DE19812331A1 (de) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
EP1100504A2 (fr) * | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Compositions pharmaceutiques et leur utilisation |
JP2002533360A (ja) | 1998-12-31 | 2002-10-08 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための3−ヘテロアリーリデニル−2−インドリノン化合物 |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
EP1309577A2 (fr) | 2000-08-11 | 2003-05-14 | Eli Lilly And Company | Derives sulfonamides heterocycliques |
US6548576B1 (en) | 2001-11-07 | 2003-04-15 | Bourns, Inc. | Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components |
GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
EA012178B1 (ru) | 2004-09-03 | 2009-08-28 | Лаборатуар Сероно Са | Пиридинметиленазолидиноны и их применение |
AU2006296369B2 (en) | 2005-09-30 | 2012-12-20 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
WO2007135529A2 (fr) * | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Composés d'azabenzimidazolyle |
JP2010508328A (ja) | 2006-11-03 | 2010-03-18 | グラクソ グループ リミテッド | Ampa受容体を強化する化合物および医薬におけるその使用 |
WO2008113795A1 (fr) | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Composés potentialisant le récepteur ampa et leurs utilisations en médecine |
GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
WO2009067607A2 (fr) | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinaisons d'inhibiteurs de pde4 et d'antipsychotiques pour le traitement de troubles psychotiques |
WO2009073777A1 (fr) | 2007-12-06 | 2009-06-11 | Schering Corporation | Modulateurs de la gamma sécrétase |
TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
WO2010005528A2 (fr) * | 2008-06-30 | 2010-01-14 | Ironwood Pharmaceuticals Incorporated | Dérivés acide carboxylique de pyrrolopyridine |
GB0822425D0 (en) | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
WO2011056985A2 (fr) | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Composés hétérocycliques substitués |
WO2011156245A2 (fr) * | 2010-06-09 | 2011-12-15 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs de mglur2 |
AR082618A1 (es) | 2010-08-10 | 2012-12-19 | Takeda Pharmaceutical | Derivados de tiadiazina, composiciones farmaceuticas y usos |
EP2603079B1 (fr) | 2010-08-12 | 2018-09-19 | Merck Sharp & Dohme Corp. | Modulateurs allostériques positifs de mglur2 |
WO2013064984A1 (fr) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryléthersulfonamides et leur utilisation en tant qu'agents thérapeutiques |
WO2013130501A1 (fr) | 2012-03-01 | 2013-09-06 | The Board Of Regents Of The University Of Texas System | Modulateurs bivalents allostériques positifs des récepteurs ampa |
GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
BR112015019276A2 (pt) | 2013-02-19 | 2017-07-18 | Pfizer | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios |
-
2016
- 2016-04-28 WO PCT/US2016/029801 patent/WO2016176460A1/fr active Application Filing
- 2016-04-28 MY MYPI2017703998A patent/MY194104A/en unknown
- 2016-04-28 CR CR20170484A patent/CR20170484A/es unknown
- 2016-04-28 MX MX2017013886A patent/MX2017013886A/es active IP Right Grant
- 2016-04-28 AU AU2016255434A patent/AU2016255434C1/en active Active
- 2016-04-28 RS RS20210362A patent/RS61688B1/sr unknown
- 2016-04-28 TW TW105113298A patent/TWI706952B/zh active
- 2016-04-28 BR BR112017023147-6A patent/BR112017023147B1/pt active IP Right Grant
- 2016-04-28 US US15/569,299 patent/US11312712B2/en active Active
- 2016-04-28 CN CN201680038830.0A patent/CN107835814B/zh active Active
- 2016-04-28 MD MDE20180234T patent/MD3288940T2/ro unknown
- 2016-04-28 EP EP22200371.7A patent/EP4144736A1/fr active Pending
- 2016-04-28 HU HUE16723204A patent/HUE053943T2/hu unknown
- 2016-04-28 JP JP2017556634A patent/JP6800886B2/ja active Active
- 2016-04-28 MA MA41988A patent/MA41988B1/fr unknown
- 2016-04-28 EP EP16723204.0A patent/EP3288940B9/fr active Active
- 2016-04-28 EA EA201792374A patent/EA033281B1/ru unknown
- 2016-04-28 BR BR122023023802-8A patent/BR122023023802A2/pt unknown
- 2016-04-28 JO JOP/2016/0085A patent/JO3654B1/ar active
- 2016-04-28 AR ARP160101217A patent/AR104447A1/es unknown
- 2016-04-28 EP EP21157913.1A patent/EP3901153A1/fr active Pending
- 2016-04-28 SI SI201631171T patent/SI3288940T1/sl unknown
- 2016-04-28 KR KR1020177034350A patent/KR20170140382A/ko active Application Filing
- 2016-04-28 UY UY0001036654A patent/UY36654A/es unknown
- 2016-04-28 ES ES16723204T patent/ES2865330T3/es active Active
- 2016-04-28 DK DK16723204.0T patent/DK3288940T5/da active
- 2016-04-28 CA CA2983826A patent/CA2983826A1/fr active Pending
- 2016-04-28 PL PL16723204T patent/PL3288940T3/pl unknown
- 2016-04-28 KR KR1020247003619A patent/KR20240017991A/ko active Application Filing
- 2016-04-28 UA UAA201711635A patent/UA120304C2/uk unknown
- 2016-04-28 PT PT167232040T patent/PT3288940T/pt unknown
- 2016-04-28 LT LTEP16723204.0T patent/LT3288940T/lt unknown
- 2016-04-28 SG SG11201708190UA patent/SG11201708190UA/en unknown
-
2017
- 2017-10-02 IL IL254848A patent/IL254848B/en active IP Right Grant
- 2017-10-03 PH PH12017501816A patent/PH12017501816A1/en unknown
- 2017-10-27 CO CONC2017/0011017A patent/CO2017011017A2/es unknown
- 2017-10-27 NI NI201700129A patent/NI201700129A/es unknown
- 2017-10-27 GT GT201700231A patent/GT201700231A/es unknown
- 2017-11-10 EC ECIEPI201774645A patent/ECSP17074645A/es unknown
- 2017-11-28 ZA ZA2017/08065A patent/ZA201708065B/en unknown
-
2018
- 2018-09-06 HK HK18111488.6A patent/HK1252249A1/zh unknown
-
2020
- 2020-07-30 AU AU2020210231A patent/AU2020210231B2/en active Active
- 2020-11-25 JP JP2020195323A patent/JP7026194B2/ja active Active
-
2021
- 2021-03-09 HR HRP20210403TT patent/HRP20210403T1/hr unknown
- 2021-04-23 CY CY20211100354T patent/CY1124059T1/el unknown
- 2021-05-19 US US17/324,520 patent/US20210284641A1/en active Pending
-
2022
- 2022-10-17 US US17/967,483 patent/US20230110576A1/en active Pending
- 2022-10-17 US US17/967,508 patent/US20230114165A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41988A (fr) | Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa | |
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
PH12015501720A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
MX363392B (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos. | |
EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
CO6501189A2 (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
GEP20156318B (en) | Heteroaryl derivatives as alpha7 nachr modulators | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
TW201613864A (en) | Novel compounds | |
EA201992679A1 (ru) | N-замещенные индольные производные | |
MX2017013877A (es) | Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MX2018015872A (es) | Derivados de benzodioxano y su uso farmaceutico. | |
NZ756915A (en) | Dual magl and faah inhibitors | |
PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
PH12016500312A1 (en) | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
MX369806B (es) | Compuestos de indolona y su uso como moduladores del receptor ampa. | |
TN2018000175A1 (en) | Indane derivatives as mglur7 modulators |